Skip to main content

Advertisement

SpringerLink
Log in

Relationship Between Low Expressions of tRNA-Derived Fragments with Metastatic Behavior of Colorectal Cancer

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Purpose

Colorectal cancer (CRC) is one of the most commonly diagnosed malignant tumors and highly heterogeneous diseases. More recently, RNA expression profiles have been used as prognostic cancer markers. In this regard, the expression of small non-coding RNAs like tRNA-derived fragments (tRFs) in tumor tissue has potential diagnostic values in metastatic cancer.

Method

Sixty postoperative CRC tissue samples, consisting of 30 cancers and 30 adjacent normal tissues, were collected from cancer patients. We evaluated MINTbase database to select tRNA-derived fragments. The expression levels of miR-1280, miR1308, tRNA-ValAAC/CAC, and tRNA-AspGTC were measured by TaqMan quantitative reverse transcription PCR technology. Also, we have evaluated the correlation between the levels of tRFs gene expression and clinicopathological of CRC disease.

Result

The three tRFs derived from tRF/miR-1280, tRNA-ValAAC/CAC, and tRNA-AspGTC downregulated in tumor tissues (all, p < 0.0001). These tRFs have lower expression in stage IV in comparison with stage III. The tRFs derived from tRNA-ValAAC (p = 0.005) and tRNA-AspGTC (p = 0.034) showed the decreased expression in CRC patients with distant metastasis.

Conclusion

The present study demonstrated that low expression of tRF/miR-1280, tRNA-ValAAC/CAC, and tRNA-AspGTC was significantly associated with metastatic stage and more aggressive tumor behavior of CRC disease. Our finding promising the potential of using tRFs as biomarkers for cancer diagnosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Availability of Data and Materials

The data and materials that support the findings of this study are available from the corresponding author upon reasonable request.

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

  2. Chen B, Morgan GJ, Barlogie B, Epstein J. Specific exosomal microRNA are differentially expressed between high and low-risk myeloma suggesting they are pathogenically important. ed: American Society of Hematology Washington, DC 2015.

  3. Balatti V, Pekarsky Y, Croce CM. Role of the tRNA-derived small RNAs in cancer: new potential biomarkers and target for therapy. Adv Cancer Res. 2017;135:173–87.

    Article  CAS  PubMed  Google Scholar 

  4. Grillone K, et al. Non-coding RNAs in cancer: platforms and strategies for investigating the genomic “dark matter.” J Exp Clin Cancer Res. 2020;39(1):1–19.

    Article  Google Scholar 

  5. Zhu L, Ge J, Li T, Shen Y, Guo J. tRNA-derived fragments and tRNA halves: the new players in cancers. Cancer Lett. 2019;452:31–7.

  6. Shan S, Wang Y, Zhu C. A comprehensive expression profile of tRNA‐derived fragments in papillary thyroid cancer. J Clin Lab Anal. 2021;35(3):e23664.

  7. Papadimitriou M-A, et al. tRNA-derived fragments (tRFs) in bladder cancer: increased 5′-tRF-LysCTT results in disease early progression and patients’ poor treatment outcome. Cancers. 2020;12(12):3661.

    Article  PubMed Central  Google Scholar 

  8. Ma Z, Zhou J, Shao Y, Jafari FA, Qi P, Li Y. Biochemical properties and progress in cancers of tRNA-derived fragments. J Cell Biochem. 2020;121(3):2058–63.

    Article  CAS  PubMed  Google Scholar 

  9. Huang B, et al. tRF/miR-1280 suppresses stem cell–like cells and metastasis in colorectal cancer. Cancer Res. 2017;77(12):3194–206.

  10. Jones C, et al. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer. 2021;107(12):1987–96.

    Article  Google Scholar 

  11. Li X, et al. Identification of aberrantly expressed miRNAs in rectal cancer. Oncol Rep 2012;28(1):77–84.

  12. Lerebours F, Clairac G, Tozlu-Kara S, Vacher S, Lidereau R, Bieche I. MicroRNA expression profiling of inflammatory breast cancer. ed: AACR.

  13. Yao D, et al. OncotRF: an online resource for exploration of tRNA-derived fragments in human cancers. RNA Biol. 2020;17(8):1081–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Zhu L, et al. Exosomal tRNA-derived small RNA as a promising biomarker for cancer diagnosis. Mol Cancer. 2019;18(1):1–5.

    Article  Google Scholar 

  15. Pliatsika V, et al. MINTbase v2. 0: a comprehensive database for tRNA-derived fragments that includes nuclear and mitochondrial fragments from all The Cancer Genome Atlas projects. Nucleic Acids Res. 2018;46(D1):D152–9.

    Article  CAS  PubMed  Google Scholar 

  16. Weiser MR. AJCC 8th edition: colorectal cancer. Ann Surg Oncol. 2018;25(6):1454–5.

    Article  PubMed  Google Scholar 

  17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods, 2001;25(4):402–8.

  18. Sun V, et al. Antitumor activity of miR-1280 in melanoma by regulation of Src. Mol Ther. 2015;23(1):71–8.

  19. Wang F, et al. A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma. Oncotarget. 2015;6(5):2709.

  20. Piepoli A, et al. Mirna expression profiles identify drivers in colorectal and pancreatic cancers. PloS One. 2012;7(3):e33663.

  21. Guo Y, et al. Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes. BMC Genomics. 2015;16(1):1–11.

    Article  Google Scholar 

  22. Goodarzi H, Liu X, Nguyen HC, Zhang S, Fish L, Tavazoie SF. Endogenous tRNA-derived fragments suppress breast cancer progression via YBX1 displacement. Cell. 2015;161(4):790–802.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Vafaei S, Fattahi F, Sahlolbei M, Kiani J, Yazdanpanah A, Madjd Z. Dynamic signature of tRNA-derived small RNAs in cancer pathogenesis as a promising valuable approach. Critical Reviews™ in Eukaryotic Gene Expression. 2020;30(5).

  24. Nientiedt M, Deng M, Schmidt D, Perner S, Müller SC, Ellinger J. Identification of aberrant tRNA-halves expression patterns in clear cell renal cell carcinoma. Sci Rep. 2016;6(1):1–9.

  25. Lee K, Ferguson LR. MicroRNA biomarkers predicting risk, initiation and progression of colorectal cancer. World J Gastroenterol. 2016;22(33):7389.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Falzone L et al. Integrated analysis of colorectal cancer microRNA datasets: Identification of microRNAs associated with tumor development. Aging (Albany NY). 2018;10(5):1000.

  27. Li H, et al. Long non-coding RNA 1308 promotes cell invasion by regulating the miR-124/ADAM 15 axis in non-small-cell lung cancer cells. Cancer Manag Res. 2018;10:6599.

  28. Lerebours F, et al. miRNA expression profiling of inflammatory breast cancer identifies a 5‐miRNA signature predictive of breast tumor aggressiveness. Int J Cancer. 2013;133(7):1614–23.

  29. He T, Zheng K, Li G, Song B, Zhang Y. Identification of typical miRNAs and target genes in hepatocellular carcinoma by DNA microarray technique. Eur Rev Med Pharmacol Sci. 2014;18(1):108–16.

    PubMed  Google Scholar 

Download references

Funding

This project was given funds from the Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran (grant number 97–4-28–13918).

Author information

Authors and Affiliations

  1. Student Research Committee, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran

    Maryam Sahlolbei

  2. Oncopathology Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran

    Maryam Sahlolbei, Fahimeh Fattahi, Somayeh Vafaei, Zahra Madjd & Jafar Kiani

  3. Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran

    Fahimeh Fattahi, Somayeh Vafaei & Jafar Kiani

  4. Department of Epidemiology, School of Public Health, North Khorasan University of Medical Sciences, Bojnurd, Iran

    Rezvan Rajabzadeh

  5. Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Aref Shiralipour

Authors
  1. Maryam Sahlolbei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fahimeh Fattahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Somayeh Vafaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rezvan Rajabzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aref Shiralipour
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zahra Madjd
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jafar Kiani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jafar Kiani.

Ethics declarations

Ethics Approval and Consent to Participate

This article was conducted under the Ethics Committee of Iran medical university (IR.IUMS.REC.1397.1121). All of the cases and controls gave their informed consent before their inclusion in the study.

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sahlolbei, M., Fattahi, F., Vafaei, S. et al. Relationship Between Low Expressions of tRNA-Derived Fragments with Metastatic Behavior of Colorectal Cancer. J Gastrointest Canc 53, 862–869 (2022). https://doi.org/10.1007/s12029-021-00773-0

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-021-00773-0

Keywords

Search

Navigation